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ABSTRACT 
Douglas James Hermes: Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme 
inhibition in a HIV-1 Tat model of neuroAIDS 
(Under the direction of Sylvia Fitting) 
cART has been proven effective in controlling HIV-1, however HAND remains a 
significant problem in patient treatment. HIV-1 Tat is a neurotoxin that contributes to the 
development of HAND and its effects are mediated via AMPAR/NMDAR activity. Enhanced 
cannabinoid signaling activity in various neurodegeneration models has been shown to be 
neuroprotective. PF3845, an inhibitor of FAAH activity, increases anandamide levels and 
produces increased neuronal survival and anti-inflammatory effects in mice with minimal side 
effects.  
PF3845 attenuates calcium equilibrium disruption, neuronal death, and dendritic 
degeneration via CB1R and CB2R mediated pathways. Incubation with CB1R and CB2R 
antagonists revealed that PF3845 calcium effects were CB1R dependent, while reduction of 
neuronal death and degeneration was CB2R dependent. PF3845 application led to increased 
levels of AEA, as well as increased levels of PEA. Our findings suggest that activation of the 
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CHAPTER 1: INTRODUCTION 
 
Combination antiretroviral therapy (cART) has greatly improved the outcome for patients 
infected with human immunodeficiency virus 1 (HIV-1), however many still exhibit mild 
neurocognitive deficits referred to as HIV-1 associated neurocognitive disorders (HAND) 
(Sacktor et al., 2002; Gannon et al., 2011; Heaton et al., 2011). Severity of HAND symptoms 
strongly correlates with synaptodendritic damage, such as dendritic simplification, axonal 
disruption, and synaptic loss (Masliah et al., 1997; Ellis et al., 2007). The HIV-1 transactivator of 
transcription (Tat) protein, a neurotoxin that likely plays a major role in the pathogenesis of 
HAND (Del Valle et al., 2000), directly disrupts healthy neuronal function by dysregulating the 
AMPA/NMDA receptor system leading to increased intracellular [Na+]i and [Ca
2+]i causing 
mitochondrial instability, enhanced cellular excitability, and swelling and/or loss of functional 
dendritic structures (Cheng et al., 1998; Haughey et al., 2001; Prendergast et al., 2002; Behnisch 
et al., 2004; Longordo et al., 2006; Brailoiu et al., 2008; Zucchini et al., 2013; Bertrand et al., 
2014; Fitting et al., 2014). Additionally, Tat promotes neuroinflammatory signaling (Nath et al., 
1999; Sheng et al., 2000; Hahn et al., 2010; Zou et al., 2011; Jin et al., 2012), which may be a 
major component of HAND pathogenesis (Mattson et al., 2005; Gannon et al., 2011; Harezlak et 
al., 2011). The persistence of HAND in the era of cART provokes questions about the causes and 
treatment of HIV-1-related brain disorders and whether cognitive deficits are reversible (Ellis et 
al., 2007).  
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Endogenous cannabinoid ligands N-arachidonoylethanolamine (anandamide/AEA) and 2-
arachidonoylglycerol (2-AG) have neuroprotective properties that likely play a role in several 
neurodegenerative disorders, including Parkinson’s and Alzheimer’s diseases (Scotter et al., 
2010; Pertwee, 2014). AEA and 2-AG primarily target cannabinoid type 1 receptors (CB1Rs) and 
cannabinoid type 2 receptors (CB2Rs), and are preferentially degraded by fatty acid amide 
hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively. Neuronal CB1R 
activation offers neuroprotection by limiting the synaptic release of glutamate (Marsicano et al., 
2003; Chevaleyre et al., 2006; Rossi et al., 2011; Chiarlone et al., 2014) and downregulating 
NMDA receptor activity (Derkinderen et al., 2003; Marsicano et al., 2003; Liu et al., 2009; Li et 
al., 2010; Hampson et al., 2011; Sanchez-Blazquez et al., 2014). Psychoactive side effects 
including sensorimotor, affective, and cognitive disturbances limit the therapeutic utility of 
CB1R agonists (Di Marzo, 2008). Further, direct application of AEA and 2-AG have poor 
clinical viability because their rapid degradation. However, inhibitors of endogenous 
cannabinoid hydrolytic enzymes show promise in overcoming these weaknesses and may prove 
effective in treating neurodegenerative disease, but this class of drugs remains to be evaluated in 
models of the neuro-acquired immune deficiency syndrome (neuroAIDS). Strong preclinical 
evidence shows that selective inhibitors of FAAH and MAGL ameliorate neurodegenerative 
disease processes in a variety of different animal models (Naidoo et al., 2011; Pertwee, 2014). 
Hydrolytic enzyme inhibitors, such as the FAAH inhibitor PF3845, show high selectivity and 
potency with minimal side effects (Ahn et al., 2009; Booker et al., 2012; Niphakis et al., 2013). 
Specifically, PF3845 increases neuronal survival, and elicits anti-nociceptive and anti-
inflammatory effects in mice without cannabimimetic side effects (Booker et al., 2012; 
Tchantchou et al., 2014). 
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The goals of this study were to test whether PF3845 produces neuroprotective effects in 
murine prefrontal cortex (PFC)-derived neuronal cultures challenged with neurotoxic 
concentrations of Tat, and to identify specific CBRs and potential mechanisms involved in 
neuroprotection. By conducting live cell [Ca2+]i imaging studies, time-lapse cell survival assays, 
and immunocytochemistry it was demonstrated that challenging cultured PFC neurons with Tat 
significantly increases neuronal [Ca2+]i levels, decreases neuron survival, and induces loss of 
dendrite structure, while preincubating cells with PF3845 ameliorates these conditions via CB1R 












CHAPTER 2: MATERIALS AND METHODS 
 
Experimental design and statistical analyses 
 The design of each experiment is detailed in methods provided for each experiment, 
including the between-subjects factors and a full description of critical variables required for 
independent replication. Data were analyzed using analyses of variance (ANOVAs) with 
Bonferroni’s correction as necessary (SPSS Statistics, Version 24, IBM). Violations of 
compound symmetry in repeated-measures ANOVAs for the within-subjects factors (i.e., 
comparing time points) were addressed by using the Greenhouse-Geisser degrees of freedom 
correction factor (Greenhouse and Geisser, 1959). An alpha level of p < 0.05 was considered 
significant for all statistical tests. Data are expressed as the mean ± standard error of the mean 
(SEM). 
Primary neuronal cultures 
 All experiments were approved by the University of North Carolina Chapel Hill 
Institutional Animal Care and Use Committee (IACUC) and conducted in accordance with the 
NIH Guide for the Care and Use of Laboratory Animals. Primary neuronal cultures were derived 
from dissociated PFC of embryonic day 15-16 C57BL/6J mice as previously described (Xu et al., 
2017). Collected tissue was minced and incubated (30 min, 37 °C) with trypsin (2.5 mg/ml) and 
DNase (0.015 mg/ml) in neurobasal medium (Invitrogen) supplemented with B27 (Invitrogen), 
L-glutamine (0.5 mM; Invitrogen), glutamate (25 mM; Sigma-Aldrich) and an antibiotic mixture 
(Invitrogen). Tissues were triturated, filtered twice through 70 µm pore nylon mesh and then 
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plated on MatTek 35mm glass bottom dishes (1 x 105 cells per dish, for calcium imaging), on 
coverslips (2 x 105 cells per coverslip, for immunocytochemistry), and on 12-well plates (2 x 105 
cells per well, for time-lapse survival assays and 3 x 105 cells per well, for mass spectrometry). 
All dishes and plates were coated with poly-L-lysine (Sigma-Aldrich) one week before use. 
Cultures were maintained in neurobasal medium supplemented with B27 (Invitrogen), 0.5 mM 
L-glutamine, 0.025 mM glutamate at 37 °C in a humidified atmosphere containing 5% CO2. All 
experiments were performed on neuronal cultures at 7-11 days in vitro (DIV) ensuring that 
dendritic/axonal structures were established and cells expressed a full complement of CBR 
proteins. 
Immunocytochemistry 
PFC neuronal cultures were fixed in 4% paraformaldehyde for 10 min, and then 
incubated in blocking buffer (1% normal goat serum, 4% BSA in 1x PBS) for 1 h at room 
temperature. Neuronal cultures were then incubated with primary antibodies against Map2ab 
(mouse, Millipore, MAB378; 1:500), and CB1R-NH (raised to amino acids 1-77 of the N-
terminus; rabbit, 1:500; (Tsou et al., 1998)) or glial fibrillary acidic protein (GFAP; rabbit, 
Millipore, AB5804; 1:500), diluted in blocking buffer, overnight at 4 °C. Primary antibodies 
were detected using appropriate secondary antibodies conjugated to either goat-anti-mouse Alexa 
488 (Molecular Probes, O-6380, 1:1000) or goat-anti-rabbit Alexa 594 (Molecular Probes, 
A11012; 1:500). Secondary antibodies were diluted in blocking buffer and applied to the 
coverslips for 1 h at room temperature. Neurons were then washed thoroughly with 1x PBS, 
counterstained with Hoechst 33342 for 3 min and mounted using ProLong Gold (Molecular 
Probes, P36930). Confocal immunofluorescent images were acquired using a Zeiss LSM 700 
laser scanning confocal microscope equipped with a 63x oil immersion objective and configured 
6 
to an Axio Observer Z.1 microscope (Zeiss, Thornwood, NY). The percent glia composition of 
neuronal cultures was calculated by dividing the number of GFAP positive cells by the total 
number of Map2ab and GFAP positive cells visualized from 10-20 randomly collected images 
from 3 independent neuronal cultures per time point (DIV 7 & DIV 11). Z-stacks for Imaris 
analysis were collected using ZEN 2010 blue Edition software (Carl Zeiss, Inc., Thornwood, 
NY) and single images were generated using the orthogonal projection function. Adobe 
Photoshop CS6 Extended 13.0 software (Adobe Systems, Inc.; San Jose, CA) was used to edit 
the images. 
Calcium imaging 
Live cell imaging was conducted on living PFC neurons in culture using a Zeiss Axio 
Observer Z.1 inverted microscope (Carl Zeiss, 20x objective) with an automated, computer-
controlled stage encoder with environmental control (37°C, 95% humidity, 5% CO2). The cell 
permeant acetoxymethyl (AM) ester-linked [Ca2+]i indicator fura-2AM (Kd = 145 nM; 2.5 µM, 
Molecular Probes) was used for measuring [Ca2+]i and diluted in Hank’s balanced salt solution 
(HBSS with Ca2+, Invitrogen) with HEPES (10 mM, Invitrogen) according to manufacturer’s 
instructions. Neurons were imaged for a 30 min period. Using ZEN 2010 blue Edition software, 
images were acquired with a MRm digital camera (Carl Zeiss) at a frame rate of 0.2 Hz during 
the first 5 min, 0.033 Hz from 5 min to 10 min, and 0.0166 Hz from 10 to 30 min. Relative 
fluorescence ratio images were acquired at 340/380 nm excitation and 510 nm emission 
wavelengths. Conversion to [Ca2+]i was calculated according to an equation described previously 
(Grynkiewicz G, Poenie et al., 1985). Regions of interest (ROIs) were manually assigned to 
neuronal somata. Due to the heterogeneity among neurons, the mean ± SEM values for changes 
in [Ca2+]i were computed comparing individual neurons before and at specific intervals during 
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treatment using a repeated-measure analysis of variance (ANOVA). Quantitative analyses of 
[Ca2+]i levels in neuronal somata were performed on 12-15 randomly selected neurons per 
treatment per experiment. At least three independent experiments were run for each treatment 
group. 
Dendrite morphology and Imaris reconstruction 
To assess changes in the dendritic length and volume of neurons, cultures were exposed 
to Tat 100 nM for 24 h before being fixed and stained against Map2ab (see above). 20-30 
neurons were imaged per condition.  Z-stacks were reconstructed as 3D images using Imaris 
software (South Windsor, CT). Dendrites were drawn using the autoloop function starting at the 
cell surface and ending at the terminus of each process. Dendrite volume was determined using 
the built-in dendrite volume reconstruction algorithm. All process length and volume values 
were calculated by Imaris and exported for statistical analysis. At least three independent 
experiments were run for each treatment group. 
Neuronal survival 
PFC neuronal survival was assessed over a 72 h time period using a Zeiss Axio Observer 
Z.1 inverted microscope (Carl Zeiss) with an automated, computer-controlled stage encoder with 
environmental control (37 °C, 95% humidity, 5% CO2). Time-lapse studies were conducted as 
previously described (Zou et al., 2011; Xu et al., 2017). PFC neurons were grown in 12-well 
plates and 6 non-overlapping fields were randomly selected per well. Individual neurons were 
then randomly selected from each field and changes in their morphology were assessed over 
time. Time-lapse images were recorded at 1 h intervals for 72 h using an automated, computer-
controlled stage encoder running Zen 2011 software (Carl Zeiss, Inc.). Neuronal death was 
assessed using rigorous morphological criteria, including neurite disintegration, loss of phase 
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brightness and fragmentation of the cell body. At least three independent experiments were run 
for each treatment. 
Lipid extraction and mass spectrometry analysis 
Cells were dissociated and collected in TrypLE (Gibco) and centrifuged at 5000g for 10 
min at 4 °C. Cells were stored at -80 °C until analysis. A seven point calibration curve ranging 
from 0.028 pmol to 2.8 pmol for anandamide (AEA), 0.033 pmol to 3.3 pmol for 
palmitoylethanolamide (PEA), and 0.031 pmol to 3.1 pmol for oleoylethanolamine (OEA). A 
negative control and blank control were also prepared.  Internal standards (10 µL of ethanol 
containing of each the following 0.28 pmol AEA-d8, 0.33 pmol PEA-d4, and 0.31 pmol OEA-
d4) was added to each calibrator, control, and sample except the blank control. Samples were 
homogenized in 100 µL of ethanol and then 900 µL of water was added. Each calibrator, control 
and sample was extracted using a UCT Clean Up® C18 sold phase extraction column (UCT, 
Inc., Bristol, PA). The columns were conditioned with 3 mL of methanol followed by 3 mL of 
deionized water.  The samples were added to the columns and aspirated followed by 2 mL of 
deionized water.  Lipids were then eluted with 2 mL of methanol.  The extracts were evaporated 
under nitrogen and reconstituted in 50 µL of mobile phase and placed in auto-sampler vial for 
Ultrahigh Performance Liquid Chromatography (UPLC) tandem mass spectrometry (MS/MS) 
analysis. UPLC-MS/MS analysis of AEA, PEA, and OEA was performed on a Sciex 6500 
QTRAP system with an IonDrive Turbo V source for TurbolonSpray® (Sciex, Ontario, Canada) 
attached to a Shimadzu UPLC system (Kyoto, Japan) controlled by Analyst software (Sciex, 
Ontario, Canada). Chromatographic separation of AEA, PEA, and OEA was performed on a 
Discovery® HS C18 Column 15 cm x 2.1mm, 3 µm (Supelco: Bellefonte, PA) kept at 25°C. The 
mobile phase consisted of A: acetonitrile and B: water with 1 g/L ammonium acetate and 0.1% 
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formic acid. The following gradient was used: 0.0 to 2.4 min at 40% A, 2.5 to 6.0 min at 40% A, 
hold for 2.1 min at 40% A, then 8.1 to 9 min 100% A, hold at 100% A for 3.1 min and return to 
40% A at 12.1 min with a flow rate was 1.0 mL/min. The source temperature was set at 600°C 
and had a curtain gas at a flow rate of 30 ml/min. The ionspray voltage was 5000 V with ion 
source gases 1 and 2 flow rates of 60 and 50 ml/min, respectively. The mass spectrometer was 
run in positive ionization mode for AEA, PEA and OEA. The acquisition mode used was 
multiple reaction monitoring (MRM). The following transition ions (m/z) with their 
corresponding collection energies (eV) in parentheses were used:  AEA: 348>62 (13) and 
348>91 (60); AEA-d8: 356>63 (13); PEA: 300>62 (28) and 300>283 (19); PEA-d4: 304>62 
(28); OEA: 326>62 (30) and 326>309 (20); OEA-d4: 330>66 (30). The total run time for the 
analytical method was 14 min. Calibration curves were analyzed with each analytical batch for 
each analyte. A linear regression of the ratio of the peak area counts of analyte and the 
corresponding deuterated internal standards versus concentration was used to construct the 
calibration curves. Final AEA, PEA and OEA concentrations were normalized by cell collection 
numbers. At least three independent experiments were run for each treatment. 
Treatments 
Neurons were treated with HIV-1 Tat1–86 (10-500 nM; ImmunoDiagnostics; clade 267 
B), PF3845 (10-100 nM, Dr. Benjamin Cravatt), CB1R antagonist SR141716a (SR1, 50 nM, 
Tocris, Ellisville, MO) and the CB2R antagonist AM630 (50 nM, Tocris, Ellisville, MO). 
Concentrations of PF3845 were chosen based on preliminary experiments (data not shown) and 
previous studies that assessed the activities of these drugs in vitro (Ahn et al., 2009; Niphakis et 
al., 2013). Tat concentrations were determined based on levels found in the HIV-1 pathological 
condition and are known to induce functional changes in neurons (Kruman et al., 1998; El-Hage 
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et al., 2008; Perry et al., 2010; El-Hage et al., 2011). For all experiments PF3845 was added 30 
min prior to experiment start. Tat was added for calcium imaging 1 min after the experiment 
started, and for neuronal survival and dendrite morphology assessments at the beginning of 
experiments. In order to determine the contribution of CB1R and/or CB2R activity to observed 
neuroprotective effects, cultures were incubated with SR1 or AM630 30 min prior to PF3845 
treatment and were present throughout the duration of the experiment. Antagonist drug 
concentrations were chosen to maximally block treatments based on preliminary explorative 




















CHAPTER 3: RESULTS 
Immunocytochemistry 
 Cell cultures were imaged to visualize cell types and determine the presence of CB1R 
(Figure 1). Differentiated neurons (DIV 7-11) were treated with antibodies specific to Map2ab 
(green), CB1R-NH (red) and counterstained with Hoechst 33342 (blue; Figure 1A). Neurons 
stained positive for Map2ab and show CB1R expression localized in the neuronal somata and 
dendritic processes. No positive CB1R staining was detected in tissue derived from CB1R 
knockout mice (data not shown). Immunocytochemistry indicates that CB1R is present in PFC 
neuronal cultures and thus may be sensitive to increases in endocannabinoid signaling following 
FAAH enzyme inhibition using PF3845. Using a primary antibody specific to GFAP (red) glial 
cells can be detected alongside neurons (Map2ab, green; Figure 1B). Quantification of percent 
glia was done on neuronal cultures at DIV 7 and DIV 11, respective to when calcium 
experiments were conducted and when neuronal survival experiments ended. A small but 
significant percentage of glia was noted in the cell population of our neuronal cultures (10.8 ± 
0.86; t(65) = 12.5, p < 0.001; Figure 1B’). A two-way ANOVA did not reveal any significant 
effects for time and treatment, indicating that the percent ratio of glia to neurons did not 
significantly change over the entirety of the experimental time course. 
Calcium imaging 
[Ca2+]i levels were assessed over time in PFC neuronal cultures to evaluate the potential 
neuroprotective effects of PF3845 after Tat exposure (Figure 2). 
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Tat increases [Ca2+]i levels in PFC cultured neurons in a concentration dependent manner 
Neurons were incubated with fura-2AM to visualize live changes in [Ca2+]i over a 30 min 
period (Figure 2A).  Application of Tat onto cultured PFC neurons induced significant changes 
in [Ca2+]i in a concentration dependent manner (Figure 2B). A two-way ANOVA showed a 
significant main effect for both, time [F(35, 10255) = 13.2, pGG < 0.001] and treatment [F(5, 
293) = 55.8, p < 0.001], and a significant treatment x time interaction effect [F(175, 10255) = 
7.0, pGG < 0.001]. A one-way ANOVA was conducted on the initial time period where [Ca
2+]i 
increases (1-5 min), and during the latter time period (20-30 min) where [Ca2+]i decreases 
slightly and plateaus. A significant treatment effect was noted for the initial (F(5, 293) = 38.3, p 
< 0.001) and the latter neuronal responses (F(5, 293) = 33.3, p < 0.001). During the initial phase, 
Tat 100 nM and 500 nM conditions significantly increased [Ca2+]i levels compared to control, 
Tat 5 nM, 10 nM, and 50 nM conditions (p < 0.001). The Tat 500 nM effect on [Ca2+]i levels was 
also significantly greater compared to the Tat 100nM treatment effect (p = 0.003). For the latter 
phase the same group differences were found as reported for the initial phase. 
PF3845 blunts Tat-mediated increases in neuronal [Ca2+]i  levels in a concentration dependent 
manner 
Pretreating cultured PFC neurons with PF3845 blunts Tat 100 nM-mediated increases in 
[Ca2+]i levels in a concentration dependent manner (Figure 2C). A two-way ANOVA revealed a 
significant main effect of time [F(35, 9625) = 11.2, pGG < 0.001] and treatment [F(5, 275) = 
14.2, p < 0.001], and a significant treatment x time interaction effect [F(175, 9625) = 2.6, pGG < 
0.001]. A one-way ANOVA conducted on the initial [Ca2+]i phase demonstrated a significant 
treatment effect [F(5, 269) = 19.7, p < 0.001] with all concentrations of PF3845 (10, 50, 100 nM) 
+ Tat 100 nM reducing [Ca2+]i levels compared to the Tat 100 nM condition (p = 0.046, p = 
0.003, p < 0.001; respectively). Note that only the PF3845 100 nM + Tat condition was able to 
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maintain [Ca2+]i levels at values that were not significantly different from control. For the latter 
phase, a one-way ANOVA also demonstrated a significant treatment effect [F(5, 268) = 7.8, p < 
0.001], with the PF3845 100 nM condition resulting in significantly reduced [Ca2+]i levels 
compared to the Tat 100 nM only condition (p = 0.002), and showing no significant difference 
from control. 
PF3845 blunting effect on [Ca2+]i  levels is CB1R, but not CB2R dependent 
  Using selective CB1R and CB2R antagonists (SR1 and AM630, respectively) it was 
determined that the specificity of PF3845’s neuroprotective effect on Tat-exposed PFC neurons 
(Figure 2D). A two-way ANOVA revealed a significant main effect for time [F(35, 9520) = 7.9, 
pGG < 0.001] and treatment [F(5, 272) = 15.4, p < 0.001], and a significant treatment x time 
interaction effect [F(175, 9520) = 2.9, pGG < 0.001]. A one-way ANOVA conducted on the 
initial [Ca2+]i  phase revealed a significant treatment effect [F(5,267) = 20.4, p < 0.001], with 
SR1 50 nM blocking the protective effect of PF3845 against Tat-induced increase in [Ca2+]i 
levels (SR1 50 nM + PF3845 100 nM + Tat 100 nM; p < 0.001 vs. control; p < 0.001 vs. PF3845 
100 nM; p = 0.04 vs. PF3845 100nM + Tat 100 nM). In contrast, the CB2R antagonist AM630 
50 nM revealed no significant difference from the PF3845 100 nM + Tat 100 nM condition and 
showed significant lower [Ca2+]i  levels from Tat 100 nM (p < 0.001), thus failing to prevent the 
protective effects of PF3845 100 nM against Tat-induced [Ca2+]i level increase. In the latter 
phase the one-way ANOVA indicated a significant treatment effect [F(5, 267) = 7.7, p < 0.001] 
with similar group differences as reported for the initial phase. 
Morphological changes quantified by Imaris analysis 
Considering synaptodendritic injury plays an essential role in the pathogenesis of HAND 
we examined Tat and FAAH enzyme inhibitor PF3845 effects after 24 h on dendritic 
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morphology (length and volume) using Imaris for quantification (Figure 3). Neurons were 
visualized as 3D representations and individual processes were analyzed (Figure 3A). A one-way 
ANOVA on total dendritic length revealed a significant treatment effect [F(5,96) = 8.3, p < 
0.001], with a significant decrease of dendritic length by all treatment conditions except PF3845 
100 nM (p < 0.001, Figure 3B). No significant difference was noted when pretreating Tat-
exposed neurons with PF3845 100 nM, suggesting no potential protective effect on dendritic 
length by PF3845. A one-way ANOVA on total dendritic volume revealed a significant 
treatment effect [F(5,96) = 16.8, p < 0.001] with a significant downregulation of dendritic 
volume by Tat 100 nM (p < 0.001, Figure 3C). Importantly, pretreating Tat-exposed neurons 
with PF3845 100 nM significantly increased volume of dendrites, indicating a protective effect 
of PF3845 against Tat-induced downregulation of dendritic volume. Interestingly, pretreating 
PF3845 100 nM + Tat 100 nM-exposed neurons with AM630 but not SR1 blocked the protective 
effects of PF3845 100 nM against Tat toxicity, implying an underlying CB2R-related mechanism 
for synaptodendritic injury after 24 h Tat treatment, specifically when looking at total dendritic 
volume. 
Neuronal survival 
Neuronal survival after PF3845 ± Tat exposure over a 72 h time period was assessed to 
evaluate the potential protective effects of PF3845 against neuronal death (Figure 4). 
Tat potentiates neuronal death in a concentration dependent manner 
Neurons were visualized using phase-contrast microscopy (Figure 4A). Challenging 
neurons with Tat for 72 h decreased neuronal viability in a Tat dose dependent fashion (Figure 
4B). A two-way ANOVA on neuronal survival demonstrated a significant main effect of time 
[F(18, 1224) = 140.8, pGG < 0.001] and a significant treatment x time interaction [F(54, 1224) = 
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3.4, pGG < 0.001]. A one-way ANOVA conducted on the last 72nd h time point indicated a 
significant treatment effect [F(3, 68) = 4.0, p = 0.011], with Tat 100 nM condition significantly 
reducing neuronal survival compared to control (p < 0.016). 
PF3845 increases neuronal survival after Tat exposure in a concentration dependent manner 
Pretreating neurons with different concentrations of PF3845 produce neuroprotective 
effects against Tat-exposure (Figure 4C). For the two-way ANOVA a significant effect was 
noted for time [F(18, 1224) = 153.3, pGG < 0.001] and treatment x time interaction [F(54, 1224) 
= 4.2, pGG < 0.001]. A one-way ANOVA on the 72nd h time point revealed a significant 
treatment effect [F(3, 68) = 4.0, p = 0.012], with Tat 100 nM and PF3845 50 nM + Tat 
significantly reducing neuronal survival compared to control (p = 0.039 and p = 0.033, 
respectively). In contrast, the higher PF3945 100 nM concentration protected against neuronal 
death, with PF3845 100 nM + Tat showing no significant difference from control. 
PF3845 protective effects on neuronal death are CB2R dependent 
Using selective CB1R and CB2R antagonists (SR1 and AM630, respectively) it was 
determined which of these receptors mediated PF3845’s neuroprotective effect against Tat-
mediated neuronal death (Figure 4D). For the two-way ANOVA a significant effect was noted 
for time [F(18, 3366) = 338.4, pGG < 0.001] and treatment x time interaction [F(72, 3366) = 4.73, 
pGG < 0.001]. A one-way ANOVA on the 72nd h time point revealed a significant treatment 
effect [F(4, 187) = 6.32, p < 0.001], with Tat and Tat + AM630 significantly reducing neuronal 
survival from control (p < 0.001). 
Mass spectrometry 
UPLC-MS/MS was used to determine the expression of AEA and other predominant 
substrates of FAAH in the presence of PF3845 100 nM ± Tat 100 nM (Figure 5). Neurons 
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exposed to PF3845 ± Tat were collected after 30 min for analysis of AEA, PEA, and OEA 
concentrations. A two-way ANOVA found a significant main effect of PF3845 for both AEA 
[F(1,12) = 6.2, p = 0.029] and PEA [F(1,12) = 6.8, p = 0.025]. As hypothesized, PF3845 100 nM 
significantly increased concentrations of some lipids targeted by FAAH, represented by an 
approximate 2-fold increase in AEA concentration and an approximate 5-fold increase in PEA 









CHAPTER 4: DISCUSSION 
 
It was demonstrated that a highly selective FAAH inhibitor, PF3845, mitigated increases 
in neuronal [Ca2+]i levels, decreases in cell survival, and loss of normal dendrite morphology in 
Tat treated murine PFC neuronal cultures by CB1R and CB2R mechanisms. 
The [Ca2+]i imaging results show that neurons exposed to Tat 100 nM significantly 
increase intracellular calcium in a stereotypical fashion (initial and latter phases of [Ca2+]i 
increase) similar to what has been described earlier (Brailoiu et al., 2008). This increase in 
calcium is a combination of Ca2+ influx as a consequence of NMDA receptor activation 
(Haughey et al., 2001; Perez et al., 2001; Longordo et al., 2006; Fitting et al., 2014) and release 
of Ca2+ from intracellular stores mediated via inositol 1,4,5-trisphosphate (IP3) and/or ryanodine 
receptor pathways (Haughey et al., 1999; Fitting et al., 2014). The Tat-mediated [Ca2+]i effect 
shows differential sensitivity to various concentrations of PF3845. While PF3845 100 nM 
significantly blunts [Ca2+]i levels across the entire time period, lower concentrations (i.e. 10 nM 
and 50 nM) only significantly blunt the initial phase of the Tat effect. Considering that the initial 
spike in Tat-mediated [Ca2+]i primarily results from Ca
2+ release from intracellular stores (Chami 
et al., 2006), the presented data suggest that Tat’s influence on IP3/ryanodine receptor pathways 
is more sensitive to PF3845 treatment than NMDAR activity. The role of CB1R in protecting 
neurons from NMDA-induced cytotoxicity has been shown to be IP3 receptor dependent (Liu et 
al., 2009), and intracellular CB1R activity has been linked with accessing lysosome and 
endoplasmic reticulum calcium stores (Brailoiu et al., 2011) suggesting
18 
that CB1R activation may disrupt the ability of Tat to exert its effects on [Ca
2+]i. CB1R has also 
been found to form heterodimers with NMDARs (Sanchez-Blazquez et al., 2014) and disrupting 
the formation of this complex has been shown to block the ability of CB1R to attenuate damage 
from excitotoxic insults (Vicente-Sanchez et al., 2013). 
While CB1R activity played a significant role in reducing Tat-mediated neurotoxicity, 
CB2R activity also played an essential role in neuronal survival and protecting against Tat-
induced decreases in dendritic volume. Using SR1 and AM630 showed that PF3845 ameliorated 
Tat mediated neuronal death and loss of dendritic structure through CB2R signaling, but 
independent of CB1R signaling. This finding suggests that the 11% glial cell component of our 
cultures (Figure 1C) likely mediates these protective effects, as glia such as murine astrocytes are 
known to express CB2R (Stella, 2010). It is important to note that similar results have been 
shown using the same culture model where a small population of glia played a role in Tat-
mediated effects (Fitting et al., 2014). Morphine was shown to potentiate Tat-mediated 
neurotoxicity via μ-opioid receptors in striatal neuronal cultures, but based on earlier findings 
these effects were found to be astrocyte specific (Zou et al., 2011), suggesting that even a small 
population of glial cells can play a significant role in influencing Tat-mediated neurotoxicity. 
Glial cells expressing CB2R’s have been demonstrated to be viable targets for protecting neurons 
from HIV-1 associated neurodegeneration as shown in several models of HAND (Price et al., 
2009; Kim et al., 2011; Hu et al., 2013), which indicates the importance of targeting 
neuroinflammatory signaling in this condition. Alternatively, evidence exists that suggests that 
CB2R is sparsely expressed in certain neuronal populations, some which have been found in the 
ventral tegmental area (VTA) and hippocampus (Zhang et al., 2016; Li and Kim, 2017). 
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Therefore, it will be necessary for further study to detect the presence or lack thereof CB2R in 
murine PFC and ascertain its potential role in influencing Tat-mediated neuronal damage. 
Disruption of synaptic structures is a major component of HAND and the prevention 
and/or reversibility of this damage is of major interest to the field (Ellis et al., 2007). In the 
present study neurons were exposed to PF3845 ± Tat and reconstructed to characterize the 
changes in neuronal dendritic morphology. Decreases in Map2ab staining in human frontal 
cortex has been associated with higher viral load and decreased neurocognitive function in HIV-
1 infected individuals (Levine et al., 2016), and direct treatment of cultured hippocampal neurons 
with Tat has been shown to decrease Map2ab expression (Butler et al., 2011). The analysis of the 
results revealed an interesting interaction between Tat and PF3845 where PF3845 failed to effect 
Tat-mediated loss of dendritic length but did preserve overall dendritic volume. Considering 
there was not a significant alteration in the total number of process filaments per neuron in each 
condition this suggests that PF3845 increases the cross-sectional area of the MAP2ab expressed 
within the individual dendritic structures. Additional experiments will be necessary to understand 
the mechanisms underlying this PF3845-mediated increase in dendritic cross-sectional area and 
its possible functional consequences. 
The neuroprotective effects of PF3845 in our Tat-exposed PFC neuronal cultures may be 
due to the elevation of AEA and/or PEA concentrations. Increases in PEA alongside AEA were 
of great interest because this non-cannabinoid fatty acid amide has been shown to produce anti-
inflammatory and neuroprotective activity through the peroxisome proliferator-activated receptor 
family (Landreth, 2007; Bright et al., 2008; Scuderi et al., 2012; Paterniti et al., 2014). A 
previous study using murine brain tissue demonstrated increased expression of endogenous N-
acylethanolamide molecules, including AEA, PEA and OEA following administration of PF3845 
20 
(Wiebelhaus et al., 2015). The lack of a significant effect of PF3845 treatment on OEA in PFC 
neuronal cultures may be due to differences in cell types present in culture vs whole brain 
lysates. 
Overall these findings indicate that inhibiting FAAH activity can protect neurons against 
Tat infliction. This raises the question if the removal of HIV-1 related stressors on neurons may 
elicit dendritic regeneration and restoration of cognitive function. Therefore, while PF3845 was 
effective in attenuating Tat-mediated neurotoxicity, it will be important to further explore 



















CHAPTER 5: CONCLUSION 
 
The presented data show the capacity of the HIV-1 Tat protein to destabilize neuronal 
calcium equilibrium, increase neuronal death, and mediate dendritic degeneration while 
application of the highly selective and potent FAAH inhibitor, PF3845, is able to attenuate these 
effects. The results of the Ca2+ experiments support the hypothesis that enhancing AEA 
concentration using PF3845 will produce neuroprotective effects via neuronal CB1R. The 
findings that the CB2R played a key role in attenuating Tat mediated increases in neuronal death 
and dendritic degeneration over 72 and 24 h, respectively, suggest that CB2Rs likely play a 
pertinent role in Tat-mediated neurodegeneration and can be targeted for therapeutic benefit by 
drugs such as PF3845. In addition, it will be important to evaluate the potential role of specific 
CB2R ligands as therapeutic drugs in treatment of HAND. Future experiments will be necessary 
to further understand the interaction between Tat and CNS resident neurons and glial cells in the 
pathogenesis of HAND, and how pharmaceutical agents targeting the endogenous cannabinoid 
















(A) Immunohistochemistry was conducted on PFC neurons (DIV 7-11) to identify cellular 
distribution of CB1R. Cells were stained for Map2ab (green) and CB1R-NH (red). CB1Rs are 
localized in the soma and dendritic processes of PFC neurons, indicating that cannabinoid 
machinery is present in the PFC primary cell culture model. Scale bars = 20 μm. (B) 
Immunohistochemistry was conducted on PFC cultures to calculate a ratio of glial cells to 
neurons. Cells were stained for Map2ab (green) and GFAP (red). (B’) GFAP staining 
demonstrates that glia showing astrocyte morphology are present in our cultures and make up 
about 11% of the cultured cells. Tat incubation did not significantly alter the percent glia 
composition of the cultures in DIV 7 and DIV 11. Statistical significance was assessed by 
ANOVA followed by Bonferroni’s post hoc test (at least three independent experiments). Scale 












Figure 2. Calcium changes in cultured PFC neurons over 30 min 
 
(A) Pseudocolor images of control and Tat conditions assessing changes in [Ca2+]i levels by 
ratiometric imaging of fura-2AM indicated minimal changes for control (white arrowheads, top 
row) but prominent changes for Tat 100 nM over a 30 min time period (white arrowheads, 
bottom row). (B) Significant Tat concentration dependent increases in [Ca2+]i levels were noted 
over 30 min with Tat 100 nM and 500 nM being significantly different from control. (C) The 
significant increase in [Ca2+]i levels by Tat 100 nM was significantly decreased by PF3845 
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pretreatment (10, 50, 100 nM) in a concentration-dependent manner (PF3845 pretreatment 30 
min prior Tat application). (D) The protective effect of PF3845 100 nM pretreatment against Tat-
induced increase in [Ca2+]i levels was blocked by SR1 50 nM but not AM630 50 nM (CBR 
antagonist pretreatment 30 min prior PF3845 application). Statistical significance was assessed 
by ANOVA followed by Bonferroni’s post hoc test; *p < 0.01 vs. control, #p < 0.05 vs. Tat 100 
nM, $p < 0.001 vs. SR1 50 nM + PF3845 100 nM + Tat 100 nM (at least three independent 















Figure 3. Morphological changes on dendrites of PFC neuronal cultures 
 
(A) Three-dimensional reconstruction of PFC neuronal dendrites at DIV 8 (B) Total dendritic 
length is significantly decreased by Tat 100 nM after 24 h. No protective effect was noted when 
pretreating Tat-exposed neurons with the FAAH enzyme inhibitor PF3845 100 nM. (C) In 
contrast, the significant reduction of total dendritic volume by Tat 100 nM was prevented with 
pretreatment of PF3845 100 nM. Interestingly, whereas SR1 50 nM was not able to block the 
protective effects of PF3845 100 nM, the CB2R antagonist AM630 50 nM was and reduced the 
dendritic volume back to the Tat 100 nM treatment condition. Statistical significance was 
assessed by ANOVA followed by Bonferroni’s post hoc test; *p < 0.01 vs. control, #p < 0.01 vs. 
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Tat 100 nM, $p < 0.001 vs. AM630 50 nM + PF3845 100 nM + Tat 100 nM (at least three 


























Figure 4. Changes in neuronal survival in cultured PFC neurons over 72 h 
 
(A) Phase images of PFC neuronal cultures of control and Tat conditions assessing neuronal 
survival in a time-lapse study over a 72 h time period. A single neuron followed for the control 
condition shows neuronal survival over 72 h (white arrowheads, top row), whereas a single 
neuron followed after exposure to Tat 100 nM died at ~ 36 h (white arrowheads, bottom row) 
although other adjacent neurons remain alive and occasionally exhibit movement during this 
time period (white arrow, bottom row). (B) Treatment of Tat 100 nM for 72 h significantly 
reduced the survival of PFC neurons in a concentration-dependent manner, with Tat 100 nM 
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being significantly different from control. (C) The significant decrease of neuronal survival by 
Tat 100 nM was significantly decreased by PF3845 100 nM pretreatment (30 min prior Tat 
application). (D) The protective effect of PF3845 100 nM pretreatment against Tat-induced 
increase in neuronal death was blocked by AM630 50 nM but not SR1 50 nM (CBR pretreatment 
30 min prior PF3845 application). Statistical significance was assessed by ANOVA followed by 
Bonferroni’s post hoc test; *p < 0.01 vs. control (at least three independent experiments). SR1: 
SR141716A. Scale bars = 20 μm. 
 
Figure 5. PF3845 mediated changes in endocannabinoid concentration in PFC neurons 
 
Concentrations of AEA, PEA, and OEA were assessed using UPLC-MS/MS after 30 min of 
PF3845 100 nM ± Tat 100 nM exposure. Lipid concentrations were normalized to cell count for 
each independent experiment. A significant main effect of PF3845 treatment was detected for 
AEA and PEA. No significant differences were noted for OEA. Statistical significance was 
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